DESCRIPCIÓN DEL ESTADO DE RECEPTORES DE ESTRÓGENO Y PROGESTERONA Y LA SOBRE-EXPRESIÓN DE ONCOPROTEÍNA C-ERBB-2 EN UNA SERIE DE 29 CASOS DE CARCINOMA DUCTAL INVASOR DE GLÁNDULA MAMARIA.

Rolando Alvarado Anchisi

Enviado octubre 18, 2024

Publicado 2026-04-06

Artículos de Investigación

Vol. 23 Núm. 1 (2010): Revista Médico Científica

DESCRIPCIÓN DEL ESTADO DE RECEPTORES DE ESTRÓGENO Y PROGESTERONA Y LA SOBRE-EXPRESIÓN DE ONCOPROTEÍNA C-ERBB-2 EN UNA SERIE DE 29 CASOS DE CARCINOMA DUCTAL INVASOR DE GLÁNDULA MAMARIA.

Rolando Alvarado Anchisi⁺⁻

PDF

Citación:

DOI: ND

Publicado: 2026-04-06

Derechos de autor 2024 Revista médico científica

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Resumen

El carcinoma ductal invasor de glándula mamaria es una entidad heterogénea, de difícil pronóstico de sobrevida global
y libre de enfermedad, debido al limitado valor de los factores pronósticos histológicos. Para esta enfermedad también existen factores que predicen la respuesta al tratamiento, como son el estado de los receptores hormonales, de estrógeno y progesterona, y la sobre-expresión de oncoproteína c-erbB-2 algunos de los cuales también constituyen factores pronósticos. Para este estudio se emplearon anticuerpos monoclonales para la determinación de receptores de estrógeno, receptores de progesterona, y oncoproteina c-erbB-2 en 29 casos referidos al Laboratorio de Patología del Hospital Chiriquí, procedentes de mujeres residentes en la provincia de Chiriquí, las cuales fueron biopsiadas del 2007 al 2009. El estudio encontró que 55,17 % corresponden a tumores tipo
luminal, 37,93 % corresponden a tumores triple negativos, y 6,90 % corresponden a tumores tipo Her2. Subestimar la importancia de estos estudios por parte de las autoridades merma la posibilidad de una terapia adecuada al pronóstico real de las pacientes con cáncer de mama.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Anderson WF, Blair A, Brinton LA et al. Established breast cancer risk factors by clinically important tumour characteristics. British Journal of Cancer 2006; 95(1): 123-129.
Anderon K, Mazouni C, Pusztal L et al. Molecular classification of breast cancer: limitations and potential. The Oncologist 2006; 11: 868-877.
Lonning PE Breast cancer prognostication and prediction: are we making progress? Annals of Oncology 2007; 18(S8): viii3-viii7.
Algrota J, Díaz de Otazu R, Fariña J et al. Immunohistochemical prognostic index for breast cancer in young women. J Clin Pathol: Mol Pathol. 2003; 56: 323-327.
Cianfrocca M, Goldstein LJ Prognostic and predictive factors in early-stage breast cancer. The Oncologist 2004; 9: 606-616.
Kroger N, Lonning T, Milde-Langosch K et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006; 12: 159-168.
Coradini D, Daidone MG Biomolecular prognostic factors in breast cancer. Current Opinion in Obstetrics and Gynecology 2004; 16: 49-55.
Aas T, Botstein D, Borresen-Dale AL et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Procedings of the National Academy of Science USA 2001; 98: 10869-10874.
Ahn SH, Gong G, Kim MJ et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human Pathology 2008; 39: 1217-1226.
Bevilacqua JLB, Carvalho FM, Fernandes RCM et al. Coordinate expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 2009; 55: 346-352.
Botstein D, Brown P, Dieterich H et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002; 161: 1991-1996.
Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopthology 2008; 52: 108-118.
Begin L, Brunet JS, Cheang MCU et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer [Internet] 2007; 7: 134 (Disponible en: http://www.biomedcentral.com)
Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple- negative phenotype. Cancer. 2007; 109: 1721-1728.
Lakhani SR. The morphology of breast tumors in BRCA1/2 carriers. Pathology Case Reviews 2003; 8: 240-244.
Delgado Y, Feiner H, Inghirami G et al. Differential amplification and overexpression of Her-2/neu, p53, MIB1, and Estrogen Receptor/Progesterone Receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med. 2003; 127: 1458-1464.
Bajdik C, Cheang MCU, Chia SK et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative
phenotype. Clin Cancer Res. 2008; 14(5): 1368-1376.
El-Sayed ME, Ellis IO, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32.
Dent R, Hanna WM, Kahn HK et al. Triple- negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-4434.
Haffty BG, Hait W, Harris L et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24: 5652-5657.
El-Rehim DMA, Ellis IO, Lee AHS et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Modern Pathology 2005; 18: 26-35.
Khan A, Khawar H, Kiani J et al. Estrogen receptor ?-negative and progesteron receptor-positive breast cancer: Lab error or real entity? Pathology Oncology Research 2006; 12: 223-227.
Scawn R, Shousha S. Morphologic spectrum of Estrogen Receptor-Negative breast carcinoma. Arch Pathol Lab Med. 2002; 126: 325-330.
Crispino S, Rastelli F. Factors predictive of response to hormone therpy in breast cancer. Tumori 2008; 94: 370-383.
Allred DC, Berardo M, Clark GM et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathology 2004; 17: 1545-15554.
Bourne P, Bu H, Hicks D et al. Bone metastasis is strongly associated with estrogen receptor- positive/progesterone receptor negative breast carcinomas. Human Pathology 2008; 39: 1809-1815.
Bohn OL, Brufsky A, Chivukula M et al. Biomarker profile in breast carcinomas presenting with bone metastasis. International Journal of Clinical and Experimental Pathology 2010; 3(2): 139-146.
Carey LA, Collichio F, Dees EC et al. The triple negative paradox: Primary tumor chemosensivity of breast cancer subtypes. Clin Cancer Res. 2007; 13: 2329-2334.
Carr JA, Divine G, Havstad S et al. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 2000; 135: 1469-1474.

Palabras clave

PDF

Resumen visto - 2 veces
PDF descargado - 1

Licencia

Content Top

[1] Anderson WF, Blair A, Brinton LA et al. Established breast cancer risk factors by clinically important tumour characteristics. British Journal of Cancer 2006; 95(1): 123-129.

[2] Anderon K, Mazouni C, Pusztal L et al. Molecular classification of breast cancer: limitations and potential. The Oncologist 2006; 11: 868-877.

[3] Lonning PE Breast cancer prognostication and prediction: are we making progress? Annals of Oncology 2007; 18(S8): viii3-viii7.

[4] Algrota J, Díaz de Otazu R, Fariña J et al. Immunohistochemical prognostic index for breast cancer in young women. J Clin Pathol: Mol Pathol. 2003; 56: 323-327.

[5] Cianfrocca M, Goldstein LJ Prognostic and predictive factors in early-stage breast cancer. The Oncologist 2004; 9: 606-616.

[6] Kroger N, Lonning T, Milde-Langosch K et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006; 12: 159-168.

[7] Coradini D, Daidone MG Biomolecular prognostic factors in breast cancer. Current Opinion in Obstetrics and Gynecology 2004; 16: 49-55.

[8] Aas T, Botstein D, Borresen-Dale AL et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Procedings of the National Academy of Science USA 2001; 98: 10869-10874.

[9] Ahn SH, Gong G, Kim MJ et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human Pathology 2008; 39: 1217-1226.

[10] Bevilacqua JLB, Carvalho FM, Fernandes RCM et al. Coordinate expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 2009; 55: 346-352.

[11] Botstein D, Brown P, Dieterich H et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002; 161: 1991-1996.

[12] Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopthology 2008; 52: 108-118.

[13] Begin L, Brunet JS, Cheang MCU et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer [Internet] 2007; 7: 134 (Disponible en: http://www.biomedcentral.com)

[14] Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple- negative phenotype. Cancer. 2007; 109: 1721-1728.

[15] Lakhani SR. The morphology of breast tumors in BRCA1/2 carriers. Pathology Case Reviews 2003; 8: 240-244.

[16] Delgado Y, Feiner H, Inghirami G et al. Differential amplification and overexpression of Her-2/neu, p53, MIB1, and Estrogen Receptor/Progesterone Receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med. 2003; 127: 1458-1464.

[17] Bajdik C, Cheang MCU, Chia SK et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative

[18] phenotype. Clin Cancer Res. 2008; 14(5): 1368-1376.

[19] El-Sayed ME, Ellis IO, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32.

[20] Dent R, Hanna WM, Kahn HK et al. Triple- negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-4434.

[21] Haffty BG, Hait W, Harris L et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24: 5652-5657.

[22] El-Rehim DMA, Ellis IO, Lee AHS et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Modern Pathology 2005; 18: 26-35.

[23] Khan A, Khawar H, Kiani J et al. Estrogen receptor ?-negative and progesteron receptor-positive breast cancer: Lab error or real entity? Pathology Oncology Research 2006; 12: 223-227.

[24] Scawn R, Shousha S. Morphologic spectrum of Estrogen Receptor-Negative breast carcinoma. Arch Pathol Lab Med. 2002; 126: 325-330.

[25] Crispino S, Rastelli F. Factors predictive of response to hormone therpy in breast cancer. Tumori 2008; 94: 370-383.

[26] Allred DC, Berardo M, Clark GM et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Modern Pathology 2004; 17: 1545-15554.

[27] Bourne P, Bu H, Hicks D et al. Bone metastasis is strongly associated with estrogen receptor- positive/progesterone receptor negative breast carcinomas. Human Pathology 2008; 39: 1809-1815.

[28] Bohn OL, Brufsky A, Chivukula M et al. Biomarker profile in breast carcinomas presenting with bone metastasis. International Journal of Clinical and Experimental Pathology 2010; 3(2): 139-146.

[29] Carey LA, Collichio F, Dees EC et al. The triple negative paradox: Primary tumor chemosensivity of breast cancer subtypes. Clin Cancer Res. 2007; 13: 2329-2334.

[30] Carr JA, Divine G, Havstad S et al. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 2000; 135: 1469-1474.

Imagen de portada

Resumen

Descargas

Citas

Palabras clave

Licencia